vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and MID PENN BANCORP INC (MPB). Click either name above to swap in a different company.
MID PENN BANCORP INC is the larger business by last-quarter revenue ($62.0M vs $37.2M, roughly 1.7× GYRE THERAPEUTICS, INC.). MID PENN BANCORP INC runs the higher net margin — 31.4% vs -3.7%, a 35.0% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 30.8%). MID PENN BANCORP INC produced more free cash flow last quarter ($71.8M vs $-5.8M). Over the past eight quarters, MID PENN BANCORP INC's revenue compounded faster (21.1% CAGR vs 17.0%).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
Commerce Bancorp was a Cherry Hill, New Jersey–based bank created in 1973. In 2007, it was purchased by Toronto-Dominion Bank, which merged Commerce into TD Banknorth, the latter of which was rebranded to TD Bank.
GYRE vs MPB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $62.0M |
| Net Profit | $-1.4M | $19.4M |
| Gross Margin | 95.3% | — |
| Operating Margin | 0.3% | 43.6% |
| Net Margin | -3.7% | 31.4% |
| Revenue YoY | 33.4% | 30.8% |
| Net Profit YoY | -340.1% | 47.0% |
| EPS (diluted) | $-0.01 | $0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.2M | $62.0M | ||
| Q3 25 | $30.6M | $61.8M | ||
| Q2 25 | $26.8M | $54.3M | ||
| Q1 25 | $22.1M | $47.7M | ||
| Q4 24 | $27.9M | $47.4M | ||
| Q3 24 | $25.5M | $45.3M | ||
| Q2 24 | $25.2M | $44.1M | ||
| Q1 24 | $27.2M | $42.3M |
| Q4 25 | $-1.4M | $19.4M | ||
| Q3 25 | $5.9M | $18.3M | ||
| Q2 25 | $1.6M | $4.8M | ||
| Q1 25 | $3.7M | $13.7M | ||
| Q4 24 | $569.0K | $13.2M | ||
| Q3 24 | $2.9M | $12.3M | ||
| Q2 24 | $4.5M | $11.8M | ||
| Q1 24 | $9.9M | $12.1M |
| Q4 25 | 95.3% | — | ||
| Q3 25 | 94.7% | — | ||
| Q2 25 | 95.7% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | 95.8% | — | ||
| Q3 24 | 96.2% | — | ||
| Q2 24 | 96.9% | — | ||
| Q1 24 | 96.4% | — |
| Q4 25 | 0.3% | 43.6% | ||
| Q3 25 | 22.7% | 39.3% | ||
| Q2 25 | 8.1% | 7.9% | ||
| Q1 25 | 10.3% | 35.2% | ||
| Q4 24 | 2.4% | 34.1% | ||
| Q3 24 | 16.6% | 32.8% | ||
| Q2 24 | 12.7% | 32.4% | ||
| Q1 24 | 29.7% | 34.8% |
| Q4 25 | -3.7% | 31.4% | ||
| Q3 25 | 19.4% | 29.6% | ||
| Q2 25 | 5.9% | 8.8% | ||
| Q1 25 | 16.9% | 28.8% | ||
| Q4 24 | 2.0% | 27.9% | ||
| Q3 24 | 11.2% | 27.1% | ||
| Q2 24 | 18.0% | 26.7% | ||
| Q1 24 | 36.6% | 28.7% |
| Q4 25 | $-0.01 | $0.83 | ||
| Q3 25 | $0.03 | $0.79 | ||
| Q2 25 | $0.00 | $0.22 | ||
| Q1 25 | $0.00 | $0.71 | ||
| Q4 24 | $0.00 | $0.72 | ||
| Q3 24 | $0.01 | $0.74 | ||
| Q2 24 | $0.01 | $0.71 | ||
| Q1 24 | $0.03 | $0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $106.0M | $814.1M |
| Total Assets | $166.1M | $6.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | — | ||
| Q3 25 | $60.0M | — | ||
| Q2 25 | $54.4M | — | ||
| Q1 25 | $29.9M | — | ||
| Q4 24 | $26.7M | — | ||
| Q3 24 | $25.1M | — | ||
| Q2 24 | $25.1M | — | ||
| Q1 24 | $37.4M | — |
| Q4 25 | $106.0M | $814.1M | ||
| Q3 25 | $101.9M | $796.3M | ||
| Q2 25 | $92.0M | $775.7M | ||
| Q1 25 | $68.1M | $667.9M | ||
| Q4 24 | $63.3M | $655.0M | ||
| Q3 24 | $63.2M | $573.1M | ||
| Q2 24 | $60.4M | $559.7M | ||
| Q1 24 | $56.6M | $551.0M |
| Q4 25 | $166.1M | $6.1B | ||
| Q3 25 | $159.4M | $6.3B | ||
| Q2 25 | $152.6M | $6.4B | ||
| Q1 25 | $129.8M | $5.5B | ||
| Q4 24 | $125.4M | $5.5B | ||
| Q3 24 | $125.2M | $5.5B | ||
| Q2 24 | $120.9M | $5.4B | ||
| Q1 24 | $122.0M | $5.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $80.0M |
| Free Cash FlowOCF − Capex | $-5.8M | $71.8M |
| FCF MarginFCF / Revenue | -15.5% | 115.8% |
| Capex IntensityCapex / Revenue | 0.4% | 13.3% |
| Cash ConversionOCF / Net Profit | — | 4.12× |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | $132.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | $80.0M | ||
| Q3 25 | $4.7M | $26.3M | ||
| Q2 25 | $2.1M | $29.0M | ||
| Q1 25 | $-129.0K | $11.5M | ||
| Q4 24 | $-2.8M | $51.4M | ||
| Q3 24 | $1.7M | $16.9M | ||
| Q2 24 | $-5.5M | $18.0M | ||
| Q1 24 | $2.9M | $12.4M |
| Q4 25 | $-5.8M | $71.8M | ||
| Q3 25 | $4.0M | $24.3M | ||
| Q2 25 | $1.8M | $27.2M | ||
| Q1 25 | $-251.0K | $8.8M | ||
| Q4 24 | $-2.8M | $44.5M | ||
| Q3 24 | $1.0M | $16.8M | ||
| Q2 24 | $-6.9M | $17.7M | ||
| Q1 24 | $2.7M | $12.1M |
| Q4 25 | -15.5% | 115.8% | ||
| Q3 25 | 13.1% | 39.4% | ||
| Q2 25 | 6.8% | 50.1% | ||
| Q1 25 | -1.1% | 18.4% | ||
| Q4 24 | -10.1% | 93.8% | ||
| Q3 24 | 4.1% | 37.1% | ||
| Q2 24 | -27.5% | 40.2% | ||
| Q1 24 | 9.8% | 28.5% |
| Q4 25 | 0.4% | 13.3% | ||
| Q3 25 | 2.2% | 3.1% | ||
| Q2 25 | 1.0% | 3.2% | ||
| Q1 25 | 0.6% | 5.7% | ||
| Q4 24 | 0.2% | 14.6% | ||
| Q3 24 | 2.7% | 0.0% | ||
| Q2 24 | 5.8% | 0.7% | ||
| Q1 24 | 0.9% | 0.8% |
| Q4 25 | — | 4.12× | ||
| Q3 25 | 0.79× | 1.44× | ||
| Q2 25 | 1.32× | 6.08× | ||
| Q1 25 | -0.03× | 0.84× | ||
| Q4 24 | -4.85× | 3.88× | ||
| Q3 24 | 0.60× | 1.37× | ||
| Q2 24 | -1.21× | 1.53× | ||
| Q1 24 | 0.29× | 1.02× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
